Understanding Sanofi’s 3Q17 Performance by Business Segment



Sanofi’s business segments

Sanofi’s (SNY) product portfolio includes various specialized and generic pharmaceutical products, vaccines, and consumer healthcare products. During 2017, Sanofi exchanged Merial, its animal health business, with the consumer healthcare business of Boehringer Ingelheim.

Sanofi now reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur (or the Human Vaccines segment).

At constant exchange rates and constant structure, SNY reported 3Q17 revenues of 9.05 billion euros, representing a 0.2% YoY (year-over-year) fall in revenues.

Article continues below advertisement

SNY’s segment-wise performance 3Q17

SNY’s Human Pharmaceuticals segment includes pharmaceutical and consumer healthcare products. The business is segregated into the following franchises:

  • Sanofi genzyme
  • general medicines and emerging markets
  • diabetes and cardiovascular products
  • consumer healthcare

The segment reported revenues of 7.14 billion euros in 3Q17—a 3.2% YoY rise in operating revenues.

Sanofi Pasteur

Sanofi Pasteur includes the revenues from the following franchises:

  • adult booster vaccines
  • meningitis vaccines
  • pneumonia vaccines
  • influenza vaccines
  • polio vaccines
  • haemophilus influenza type b (or HIB) vaccines
  • pertussis vaccines
  • travel and other endemics vaccines

Sanofi Pasteur reported revenues of 1.92 billion euros in 3Q17, which was 11% higher YoY.

Notably, the First Trust BuyWrite Income ETF (FTHI) has 12% of its total investments in healthcare companies, with 0.2% in Sanofi ADR (SNY), 1.3% in Gilead Sciences (GILD), 2.4% in Allergan (AGN), and 2.4% in Johnson & Johnson (JNJ).


More From Market Realist